Encapsulation of Alpha-1 antitrypsin in PLGA nanoparticles: In Vitro characterization as an effective aerosol formulation in pulmonary diseases

[1]  Hirenkumar K. Makadia,et al.  Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. , 2011, Polymers.

[2]  E. Haller,et al.  Initial Observations of Cell-Mediated Drug Delivery to the Deep Lung , 2011, Cell transplantation.

[3]  S. Semple,et al.  α 1 -Antitrypsin: Anti-inflammatory roles in exercise and atherosclerosis , 2011 .

[4]  S. Bhatia.  Biomaterials for Clinical Applications , 2010 .

[5]  Frederic Lagarce,et al.  Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. , 2010, Nanomedicine.

[6]  I. Oglesby,et al.  Anti-apoptotic effects of Z α1-antitrypsin in human bronchial epithelial cells , 2009, European Respiratory Journal.

[7]  D. Lomas,et al.  alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies. , 2009, Clinical science.

[8]  P. Lin,et al.  Current advances in research and clinical applications of PLGA-based nanotechnology , 2009, Expert review of molecular diagnostics.

[9]  M. Bhasin,et al.  Curative and β cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice , 2008, Proceedings of the National Academy of Sciences.

[10]  K. Müllen,et al.  Oil-in-oil emulsions: a unique tool for the formation of polymer nanoparticles. , 2008, Accounts of chemical research.

[11]  M. Gulisano,et al.  Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity , 2008, BMC Cancer.

[12]  M. Miravitlles,et al.  [Alpha-1 antitrypsin deficiency: diagnosis and treatment]. , 2008, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[13]  Malgorzata Smola,et al.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases , 2008, International journal of nanomedicine.

[14]  Tejraj M Aminabhavi,et al.  Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[15]  R. Peters,et al.  From fluorescence nanoscopy to nanoscopic medicine. , 2008, Nanomedicine.

[16]  Steven J Siegel,et al.  Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. , 2008, International journal of pharmaceutics.

[17]  V. Mohanraj,et al.  Nanoparticles - A Review , 2007 .

[18]  Toshinori Yoshida,et al.  Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. , 2007, Physiological reviews.

[19]  I. J. van der Klei,et al.  The significance of peroxisomes in methanol metabolism in methylotrophic yeast. , 2006, Biochimica et biophysica acta.

[20]  S. Hasannia,et al.  Elevated expression of human alpha-1 antitrypsin mediated by yeast intron in Pichia pastoris , 2006, Biotechnology Letters.

[21]  J. Teckman,et al.  Alpha-1-antitrypsin deficiency: Diagnosis, pathophysiology, and management , 2006, Current gastroenterology reports.

[22]  D. Rudnick,et al.  Alpha‐1‐antitrypsin deficiency: A new paradigm for hepatocellular carcinoma in genetic liver disease , 2005, Hepatology.

[23]  S. Cryan,et al.  Carrier-based strategies for targeting protein and peptide drugs to the lungs , 2005, The AAPS Journal.

[24]  P. Hoet,et al.  Nanoparticles – known and unknown health risks , 2004, Journal of nanobiotechnology.

[25]  P. Scanlon.  THE PATHOGENESIS AND PATHOLOGY OF COPD: IDENTIFYING RISK FACTORS AND IMPROVING MORBIDITY AND MORTALITY * , 2004 .

[26]  M. Dolovich,et al.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. , 2003, British journal of clinical pharmacology.

[27]  Jagdish Singh,et al.  Lysozyme Stability in Primary Emulsion for PLGA Microsphere Preparation: Effect of Recovery Methods and Stabilizing Excipients , 2002, Pharmaceutical Research.

[28]  R. Stockley.  Neutrophils and the pathogenesis of COPD. , 2002, Chest.

[29]  Kinam Park,et al.  Microencapsulation methods for delivery of protein drugs , 2001 .

[30]  D. Lomas,et al.  Pathogenic α1-Antitrypsin Polymers Are Formed by Reactive Loop-β-Sheet A Linkage* , 2000, The Journal of Biological Chemistry.

[31]  Pasupathy Sivasothy,et al.  Pathogenic alpha(1)-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage , 1999 .

[32]  K. Shakesheff,et al.  Polymeric systems for controlled drug release. , 1999, Chemical reviews.

[33]  D. Mattey,et al.  Comparison of IgA-alpha1-antitrypsin levels in rheumatoid arthritis and seronegative oligoarthritis: complex formation is not associated with inflammation per se. , 1998, British journal of rheumatology.

[34]  J. Katz,et al.  α1-Antitrypsin Blocks the Release of Transforming Growth Factor-α from MCF-7 Human Breast Cancer Cells1 , 1997 .

[35]  M. E. Hazmi.  Alpha-1-antitrypsin deficiency: an overview of recent advances. , 1996, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[36]  R. Crystal,et al.  Aerosol α1 -antitrypsin treatment for cystic fibrosis , 1991, The Lancet.

[37]  N. Kalsheker.  Alpha1-antitrypsin: Structure, function and molecular biology of the gene , 1989, Bioscience reports.

[38]  K. Devi,et al.  International Journal of PharmTech Research , 2012 .

[39]  W. Seeger,et al.  Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models , 2011 .

[40]  H. Mansour,et al.  Nanopharmaceuticals I: Nanocarrier systems in drug delivery , 2011 .

[41]  D. Sakarkar,et al.  NANOPARTICLES-TREMENDOUS THERAPEUTIC POTENTIAL:A REVIEW , 2009 .

[42]  N. McElvaney,et al.  Targeting neutrophil elastase in cystic fibrosis. , 2008, Expert opinion on therapeutic targets.

[43]  M. Atkinson,et al.  71. Alpha 1 Antitrypsin (AAT) Gene Therapy for the Prevention of Type 1 Diabetes , 2006 .

[44]  M. Dolovich,et al.  Labiris, N.R. & Dolovich, M.B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56, 588-599 , 2004 .

[45]  Ann-Christine Albertsson,et al.  Degradable polymer microspheres for controlled drug delivery , 2002 .

[46]  A. N. Alzouki.  The role of alpha1 -antitrypsin Deficiency in the Pathogenesis of Antineutrophil Cytoplasmic Antibodies Associated Systemic Necrotizing Vasculitides. , 1999, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[47]  R. Burton.  A MECHANISTIC APPROACH , 1990 .